CTCs in primary breast cancer (I)

Area of Science:

• Oncology
• Biomarkers
• Cancer Research

Background:

• Circulating tumor cells (CTCs) are increasingly studied for their prognostic and predictive value in primary breast cancer.
• Previous research indicates CTC presence in a significant percentage of patients before and after neoadjuvant chemotherapy, without clear correlation to tumor characteristics or response.

Purpose of the Study:

• To evaluate the prognostic significance of CTCs in a large cohort of primary breast cancer patients.
• To determine if CTC presence and quantity predict disease-free survival (DFS) and overall survival (OS).

Main Methods:

• A major trial analyzed 2,026 primary breast cancer patients post-resection and pre-adjuvant chemotherapy for CTC presence.
• Multivariate analysis was used to assess the association between CTCs and patient outcomes.
• Subgroup analyses examined CTC persistence after chemotherapy.

Main Results:

• CTC prevalence was 22% before adjuvant chemotherapy.
• CTC presence was an independent predictor of worse DFS (HR 1.88) and OS (HR 1.91).
• Higher CTC counts (≥5) significantly increased the risk of recurrence or death (HR 4.04 for DFS, 3.05 for OS). Persisting CTCs post-chemotherapy correlated with decreased DFS.

Conclusions:

• CTC detection is a valuable prognostic tool in primary breast cancer, identifying patients at higher risk of relapse.
• The quantity of CTCs is directly associated with poorer outcomes.
• Further research is needed to establish CTCs for treatment monitoring and as therapeutic targets.